Top

Published in:

01-08-2017 | Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

Authors: Philmo Oh, Kevin L. Du

Published in: Current Colorectal Cancer Reports | Issue 4/2017

Abstract

Neoadjuvant chemoradiation has been a standard of care for locally advanced rectal cancers. Recent reports suggest that a pathologic complete response to neoadjuvant treatment correlates to improved overall survival. In addition, some series suggest that patients who have a complete response to neoadjuvant therapy may safely defer surgery in favor of a “watch and wait” approach, therefore avoiding the potential complications and adverse bowel function associated with surgery. It is therefore important to understand the clinical and biologic factors which affect the response of rectal cancers to chemoradiation. This review highlights the current literature examining the biomarkers of tumor response to chemoradiation.

Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–27. doi:10.1001/jamaoncol.2015.0735.CrossRef

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.21332.CrossRefPubMed

• Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33. doi:10.1200/JCO.2011.40.1836. This trial established the use of neoadjuvant chemoradiation in locally advanced rectal cancer. CrossRefPubMed

Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827–33. doi:10.1200/JCO.2012.42.9597.CrossRefPubMed

Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–23. doi:10.1002/bjs.5506.CrossRefPubMed

• Habr-Gama A, Gama-Rodrigues J, Sao Juliao GP, Proscurshim I, Sabbagh C, Lynn PB, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88(4):822–8. doi:10.1016/j.ijrobp.2013.12.012. A key study demonstrating the feasibility of the watch and wait approach with early salvage surgery. CrossRefPubMed

Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44. doi:10.1016/S1470-2045(10)70172-8.CrossRefPubMed

Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99(7):918–28. doi:10.1002/bjs.8702.CrossRefPubMed

• Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89. doi:10.1016/S1470-2045(15)00159-X. The addition of oxaliplatin increased preoperative acute grade 3–4 toxicities but also increased 3 year DFS. CrossRefPubMed

10.

• Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957–66. doi:10.1016/S1470-2045(15)00004-2. This study demonstrates increased pCR with intensification of neoadjuvant therapy at the expense of increased toxicities. CrossRefPubMedPubMedCentral

11.

van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82. doi:10.1016/S1470-2045(11)70097-3.CrossRefPubMed

12.

Ellis CT, Samuel CA, Stitzenberg KB. National trends in nonoperative management of rectal adenocarcinoma. J Clin Oncol. 2016;34(14):1644–51. doi:10.1200/JCO.2015.64.2066.CrossRefPubMed

13.

Torok JA, Palta M, Willett CG, Czito BG. Nonoperative management of rectal cancer. Cancer. 2016;122(1):34–41. doi:10.1002/cncr.29735.CrossRefPubMed

14.

Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006;10(10):1319–1328; discussion 28–9. doi:10.1016/j.gassur.2006.09.005.CrossRefPubMed

15.

•• Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7. discussion 7–8 This is the demonstration with long term follow up demonstrating excellent results without surgery in patients with a complete clinical response. PubMedPubMedCentral

16.

• Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–40. doi:10.1200/JCO.2011.37.7176. A series from MSKCC also demonstrating the potential of non-operative management after a complete response to neoadjuvant therapy in locally advanced rectal cancer. CrossRefPubMed

17.

Smith JD, Ruby JA, Goodman KA, Saltz LB, Guillem JG, Weiser MR, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256(6):965–72. doi:10.1097/SLA.0b013e3182759f1c.CrossRefPubMed

18.

van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6. doi:10.1038/415530a.CrossRef

19.

Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31(14):1775–81. doi:10.1200/JCO.2012.45.1096.CrossRefPubMedPubMedCentral

20.

Kim IJ, Lim SB, Kang HC, Chang HJ, Ahn SA, Park HW, et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum. 2007;50(9):1342–53. doi:10.1007/s10350-007-277-7.CrossRefPubMed

21.

Brettingham-Moore KH, Duong CP, Greenawalt DM, Heriot AG, Ellul J, Dow CA, et al. Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma. Clin Cancer Res. 2011;17(9):3039–47. doi:10.1158/1078-0432.CCR-10-2915.CrossRefPubMed

22.

• Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol. 2005;23(9):1826–38. doi:10.1200/JCO.2005.00.406. This study identified a gene set from pretreatment biopsies collected in the German Rectal Cancer Trial. CrossRefPubMedPubMedCentral

23.

Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K, et al. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol. 2008;6(1):53–61. doi:10.1016/j.cgh.2007.10.022.CrossRefPubMed

24.

Lopes-Ramos C, Koyama FC, Habr-Gama A, Salim AC, Bettoni F, Asprino PF, et al. Comprehensive evaluation of the effectiveness of gene expression signatures to predict complete response to neoadjuvant chemoradiotherapy and guide surgical intervention in rectal cancer. Cancer Genet. 2015;208(6):319–26. doi:10.1016/j.cancergen.2015.03.010.CrossRefPubMed

25.

•• Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6. doi:10.1038/nm.3967. This is an excellent resource that for the first time pooled several large datasets to generate consensus molecular subtypes in colorectal cancer. CrossRefPubMedPubMedCentral

26.

Nicholson BD, Shinkins B, Pathiraja I, Roberts NW, James TJ, Mallett S, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015;12:CD011134. doi:10.1002/14651858.CD011134.pub2.

27.

Wallin U, Rothenberger D, Lowry A, Luepker R, Mellgren A. CEA—a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer. Dis Colon Rectum. 2013;56(7):859–68. doi:10.1097/DCR.0b013e31828e5a72.CrossRefPubMed

28.

Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007;109(9):1750–5. doi:10.1002/cncr.22625.CrossRefPubMed

29.

Zeng WG, Liang JW, Wang Z, Zhang XM, Hu JJ, Hou HR, et al. Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Chin J Cancer. 2015;34(10):468–74. doi:10.1186/s40880-015-0033-7.PubMed

30.

Kleiman A, Al-Khamis A, Farsi A, Kezouh A, Vuong T, Gordon PH, et al. Normalization of CEA levels post-neoadjuvant therapy is a strong predictor of pathologic complete response in rectal cancer. J Gastrointest Surg. 2015;19(6):1106–12. doi:10.1007/s11605-015-2814-3.CrossRefPubMed

31.

Yang KL, Yang SH, Liang WY, Kuo YJ, Lin JK, Lin TC, et al. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol. 2013;8:43. doi:10.1186/1748-717X-8-43.CrossRefPubMedPubMedCentral

32.

Agostini M, Pucciarelli S, Enzo MV, Del Bianco P, Briarava M, Bedin C, et al. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol. 2011;18(9):2461–8. doi:10.1245/s10434-011-1638-y.CrossRefPubMed

33.

Pucciarelli S, Rampazzo E, Briarava M, Maretto I, Agostini M, Digito M, et al. Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2012;19(9):3089–96. doi:10.1245/s10434-012-2272-z.CrossRefPubMed

34.

•• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4. doi:10.1126/science.1129139. This is the first publication demonstrating the potential of using characteristics of the immune microenvironment to predict outcomes. CrossRefPubMed

35.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–8. doi:10.1200/JCO.2010.30.5425.CrossRefPubMed

36.

Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944–51. doi:10.1200/JCO.2008.19.6147.CrossRefPubMed

37.

•• Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20(7):1891–9. doi:10.1158/1078-0432.CCR-13-2830. The authors demonstrate that the pretreatment density of T cell infiltrate is predictive of response to neoadjuvant chemoradiation. CrossRefPubMed

38.

Lote H, Cafferkey C, Chau I. PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treat Rev. 2015;41(10):893–903. doi:10.1016/j.ctrv.2015.09.004.CrossRefPubMed

39.

Saigusa S, Toiyama Y, Tanaka K, Inoue Y, Mori K, Ide S, et al. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. Int J Clin Oncol. 2016;21(5):946–52. doi:10.1007/s10147-016-0962-4.CrossRefPubMed

40.

Shinto E, Hase K, Hashiguchi Y, Sekizawa A, Ueno H, Shikina A, et al. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2014;21(Suppl 3):S414–21. doi:10.1245/s10434-014-3584-y.CrossRefPubMed

41.

McCoy MJ, Hemmings C, Anyaegbu CC, Austin SJ, Lee-Pullen TF, Miller TJ, et al. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. Oncotarget. 2017; doi:10.18632/oncotarget.15048.

42.

McCoy MJ, Hemmings C, Miller TJ, Austin SJ, Bulsara MK, Zeps N, et al. Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. Br J Cancer. 2015;113(12):1677–86. doi:10.1038/bjc.2015.427.CrossRefPubMedPubMedCentral

43.

Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181–4. doi:10.1002/jso.20329.CrossRefPubMed

44.

Kim IY, You SH, Kim YW. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surg. 2014;14:94. doi:10.1186/1471-2482-14-94.CrossRefPubMedPubMedCentral

45.

Dou X, Wang RB, Yan HJ, Jiang SM, Meng XJ, Zhu KL, et al. Circulating lymphocytes as predictors of sensitivity to preoperative chemoradiotherapy in rectal cancer cases. Asian Pac J Cancer Prev. 2013;14(6):3881–5.CrossRefPubMed

46.

Hasegawa S, Eguchi H, Tomokuni A, Tomimaru Y, Asaoka T, Wada H, et al. Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer. Oncol Lett. 2016;11(2):1560–6. doi:10.3892/ol.2015.4057.PubMed

47.

Choi CH, Kim WD, Lee SJ, Park WY. Clinical predictive factors of pathologic tumor response after preoperative chemoradiotherapy in rectal cancer. Radiat Oncol J. 2012;30(3):99–107. doi:10.3857/roj.2012.30.3.99.CrossRefPubMedPubMedCentral

48.

Lino-Silva LS, Salcedo-Hernandez RA, Ruiz-Garcia EB, Garcia-Perez L, Herrera-Gomez A. Pre-operative neutrophils/lymphocyte ratio in rectal cancer patients with preoperative chemoradiotherapy. Med Arch. 2016;70(4):256–60. doi:10.5455/medarh.2016.70.256-260.PubMedPubMedCentral

49.

Shen J, Zhu Y, Wu W, Zhang L, Ju H, Fan Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Med Sci Monit. 2017;23:315–24.CrossRefPubMedPubMedCentral

50.

Group MS. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333(7572):779. doi:10.1136/bmj.38937.646400.55.CrossRef

51.

•• Taylor FG, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol. 2014;32(1):34–43. doi:10.1200/JCO.2012.45.3258. This is a well-designed clinical trial designed to assess accuracy of MRI in predicting the pathologic surgical margin. CrossRefPubMed

52.

Lambrecht M, Vandecaveye V, De Keyzer F, Roels S, Penninckx F, Van Cutsem E, et al. Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int J Radiat Oncol Biol Phys. 2012;82(2):863–70. doi:10.1016/j.ijrobp.2010.12.063.CrossRefPubMed

53.

Genovesi D, Filippone A, Ausili Cefaro G, Trignani M, Vinciguerra A, Augurio A, et al. Diffusion-weighted magnetic resonance for prediction of response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: preliminary results of a monoinstitutional prospective study. Eur J Surg Oncol. 2013;39(10):1071–8. doi:10.1016/j.ejso.2013.07.090.CrossRefPubMed

54.

Sun YS, Zhang XP, Tang L, Ji JF, Gu J, Cai Y, et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology. 2010;254(1):170–8. doi:10.1148/radiol.2541082230.CrossRefPubMed

55.

Tong T, Sun Y, Gollub MJ, Peng W, Cai S, Zhang Z, et al. Dynamic contrast-enhanced MRI: use in predicting pathological complete response to neoadjuvant chemoradiation in locally advanced rectal cancer. J Magn Reson Imaging. 2015;42(3):673–80. doi:10.1002/jmri.24835.CrossRefPubMed

56.

George ML, Dzik-Jurasz AS, Padhani AR, Brown G, Tait DM, Eccles SA, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg. 2001;88(12):1628–36. doi:10.1046/j.0007-1323.2001.01947.x.CrossRefPubMed

57.

Intven M, Reerink O, Philippens ME. Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neo-adjuvant chemoradiation. J Magn Reson Imaging. 2015;41(6):1646–53. doi:10.1002/jmri.24718.CrossRefPubMed

58.

Martoni AA, Di Fabio F, Pinto C, Castellucci P, Pini S, Ceccarelli C, et al. Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol. 2011;22(3):650–6. doi:10.1093/annonc/mdq433.CrossRefPubMed

59.

Huh JW, Min JJ, Lee JH, Kim HR, Kim YJ. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation. Am J Clin Oncol. 2012;35(4):340–4. doi:10.1097/COC.0b013e3182118e7d.CrossRefPubMed

60.

Niccoli-Asabella A, Altini C, De Luca R, Fanelli M, Rubini D, Caliandro C, et al. Prospective analysis of 18F-FDG PET/CT predictive value in patients with low rectal cancer treated with neoadjuvant chemoradiotherapy and conservative surgery. Biomed Res Int. 2014;2014:952843. doi:10.1155/2014/952843.PubMedPubMedCentral

61.

Capirci C, Rubello D, Pasini F, Galeotti F, Bianchini E, Del Favero G, et al. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. Int J Radiat Oncol Biol Phys. 2009;74(5):1461–9. doi:10.1016/j.ijrobp.2008.10.064.CrossRefPubMed

62.

• Dunne PD, McArt DG, Bradley CA, O'Reilly PG, Barrett HL, Cummins R, et al. Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer. Clin Cancer Res. 2016;22(16):4095–104. doi:10.1158/1078-0432.CCR-16-0032. This work highlights the caveats of using the CMS subtypes and potential source of variability as a result of intratumor heterogeneity. CrossRefPubMed

63.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. doi:10.1056/NEJMoa1500596.CrossRefPubMedPubMedCentral

64.

Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582–9. doi:10.1097/SLA.0b013e3181b91e63.PubMed

65.

Wolthuis AM, Penninckx F, Haustermans K, De Hertogh G, Fieuws S, Van Cutsem E, et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol. 2012;19(9):2833–41. doi:10.1245/s10434-012-2327-1.CrossRefPubMed

66.

Sanghera P, Wong DW, McConkey CC, Geh JI, Hartley A. Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol). 2008;20(2):176–83. doi:10.1016/j.clon.2007.11.013.CrossRef

67.

Appelt AL, Ploen J, Vogelius IR, Bentzen SM, Jakobsen A. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(1):74–80. doi:10.1016/j.ijrobp.2012.05.017.CrossRefPubMed

Title: Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Authors: Philmo Oh
Kevin L. Du
Publication date: 01-08-2017
Publisher: Springer US
Published in: Current Colorectal Cancer Reports / Issue 4/2017
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI: https://doi.org/10.1007/s11888-017-0376-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Adenomatous Polyposis Syndromes: Familial Adenomatous Polyposis and MutYH-Associated Polyposis

The Role of CT Colonography as a Screening Tool for Colorectal Cancer

Colorectal Cancer Surveillance: What Is the Optimal Frequency of Follow-up and Which Tools Best Predict Recurrence?

Quality Colorectal Cancer Screening: Endoscopic Performance Measures and Beyond

Clinical Target Volume Definition in Preoperative Radiotherapy of Rectal Carcinoma: a Systematic Review

Treatment of Refractory Colorectal Cancer: Regorafenib vs. TAS-102

Keynote webinar | Spotlight on antibody–drug conjugates in cancer